Q-omics provides the consensus-scored PDZD7 profile across patient tissues and cancer cell-line models. PDZD7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDZD7 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PDZD7 RNA expression shows 16,770 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where PDZD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZD7 survival associations across molecular data types. PDZD7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZD7 RNA expression–survival associations across cancer types. High PDZD7 expression shows unfavorable associations in KIRC, UVM, KICH, LUSC and THCA, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDZD7 RNA expression.
This table summarizes PDZD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PDZD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZD7 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, THCA, LIHC and BRCA. The COAD box plot shows higher PDZD7 RNA expression in tumor versus normal tissue (log2 FC = +0.779, t-test p < 0.001).
This table shows molecular features associated with PDZD7 in patient tissues and cancer cell lines. In patient samples, PDZD7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDZD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
